Extract from the Register of European Patents

EP Citations: EP4274824

Cited inInternational search
Type:Patent literature
Publication No.:WO2008154241  [X]
 (ABBOTT LAB [US], et al) [X] 1-3,5-9,11,13-17,39 * N- [5 -( 1 -benzyl-5 -cyclopropyl- IH-1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]-N'-ethylurea; N-benzyl-N'-[5 -( 1 -benzyl-5 -cyclopropyl- 1 H- 1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]urea; N- [5.( l -benzyl- 1 H- 1 ,2,3 -triazol-4-yl)- 1 H-indazol-3 -yl]-N'-propylurea; N-[5-(l-benzyl-lH-l,2,3-triazol-4-yl)-lH-indazol-3-yl]-N'-ethylurea;; pages 13-27; examples 260, 319, 322 *;
Type:Patent literature
Publication No.:WO2008156757  [X]
 (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1,2,4,5,7,11 * Reference example 43 *;
Type:Patent literature
Publication No.:WO2009112275  [X]
 (BAYER CROPSCIENCE AG [DE], et al) [X] 1,5-8,11,13-17 * compounds 4-47, 4-60 *;
Type:Patent literature
Publication No.:WO2011133882  [X]
 (CYTOKINETICS INC [US], et al) [X] 1-3,9,11,13,14,36 * Page 188 1st compound Page 221 2nd compound *;
Type:Patent literature
Publication No.:WO2017189663  [X]
 (ENANTA PHARM INC [US]) [X] 1,4,7,12,14,36 * compounds 345-350, 354, 368-373 *;
Type:Patent literature
Publication No.:WO2020010155  [Y]
 (IFM DUE INC [US]) [Y] 1-39 * claims 1-15, 19-114, 116-170 *;
Type:Patent literature
Publication No.:WO2020150417  [Y]
 (IFM DUE INC [US]) [Y] 1-39* claims 1-26, 30-127, 136-278 *
Cited inby applicant
Type:Patent literature
Publication No.:US7927613  
Type:Patent literature
Publication No.:US2012202848  
Type:Patent literature
Publication No.:WO2015061294  
Type:Non-patent literature
Publication information:   - LAMMERS et al., "Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems", Neoplasia, (20060000), vol. 10, pages 788 - 795
Type:Non-patent literature
Publication information:   - FILIPSKI, K.J. et al., Current Topics in Medicinal Chemistry, (20130000), vol. 13, pages 776 - 802